The findings are published this week in the Proceedings of the National Academy of Sciences (PNAS) and provide the foundation for future antiviral drug and vaccine
development against the virus, rhinovirus C.
Not exact matches
That
development is important because a T cell response will likely confer longer - term protection than current inoculations do and defend
against a variety of flu strains (because T cells would be on the lookout for several different features of the flu
virus whereas antibodies would be primarily focused on the shape of a specific strain).
We are making efforts to apply these findings in the
development of drugs
against viruses such as human parainfluenza
virus,» Professor Sakaguchi described.
Just over a year ago, the same team of South African researchers reported in Nature Medicine (also part of the Nature group of journals) on their discovery relating to two other KwaZulu - Natal women, that a shift in the position of one sugar molecule on the surface of the
virus led to the
development of broadly neutralizing antibodies
against HIV.
Thus these plant extracts may be useful starting material for the
development of potent herbal agents
against selected
virus infections.
The first live - attenuated Zika vaccine still in the
development stage completely protected mice
against the
virus after a single vaccination dose, according to new research from The University of Texas Medical Branch at Galveston and Instituto Evandro Chagas at the Ministry of Health in Brazil.
This small molecule is in clinical trials
against cancer and has high specificity and good pharmacological properties, which could warrant its further
development as antiviral drug for treatment of pH1N1
virus infection,» Dr. Oxana Denisova says.
«Drugs approved to treat hepatitis C and compounds in
development to treat other viral diseases are prime candidates to use
against the Zika
virus,» Kao said.
«As such, the
development of effective countermeasures
against these
viruses is a critical need.»
«The discovery of novel intracellular receptors for
viruses, like LAMP1 for Lassa
virus, opens the door for the
development of therapeutics directed
against these previously unknown targets,» said Dye.
A major goal of HIV - 1 vaccine
development is to identify immunogens capable of inducing protective titers of broadly neutralizing antibodies (bNAbs)
against circulating, neutralization - resistant (tier 2)
viruses.
«As eliciting a highly diverse immune response may be favorable to providing protection
against incredibly diverse HIV - 1 variants in global circulation,» the researchers conclude that their study «supports further investigations of the molecular and functional characteristics of the
virus - antibody interplay in superinfected individuals, as superinfection may provide insight to the
development of a diverse Nab response with multiple epitope specificities.»
The structure could inform vaccine
development, as the Zika E glycoprotein is a key target of immune responses
against the
virus.
In conclusion, the antibodies characterized herein show promise for
development as broadly reactive therapeutic agents
against the pandemic H1N1 influenza
virus, as well as
against the majority of H1N1 and H5N1 influenza strains.
Dr Peter Barlow says study represents a promising step forward in the rapid
development of a safe and robust vaccine
against Zika
virus infection in humans.
We have completed the active phase of a Phase 1 trial of a Vaxwave ® - based vaccine
against cytomegalovirus (CMV) and are finalizing clinical
development plans for TheraT ® in Human Papilloma
Virus (HPV)- related head and neck cancers.
«It also was effective
against known drug - resistant strains of the HIV
virus, making it a very promising candidate for further
development into a new HIV drug.»
«These findings certainly raise optimism that the
development of a safe and effective vaccine
against Zika
virus for humans may be successful,» he said.
The chronically stressed mice had decreased immune function and experienced tumor
development significantly earlier than the non-stressed mice.16 Other mouse studies of ovarian cancer showed that chronic stress resulted in increased cancer growth as well as increased angiogenesis, the process with which cancer forms new blood vessels to feed itself nutrients for growth and metastases.17 Chronic stress has also been shown to decrease our body's ability to mount an attack
against foreign invaders, including
viruses.18 As we know that several
viruses can cause cancer (HPV and cervical cancer, and EBV and nasopharyngeal cancer), we can extrapolate that any decrease in immune function could increase cancer risk.
Additional Foundation - funded studies helped lay the groundwork for the
development of the first vaccine
against feline leukemia
virus.
development of a novel vaccine strategy
against feline enteric coronavirus, the nonlethal
virus that can mutate into the FIP
virus
In human medicine, our growing knowledge about the role of
viruses as a cause of certain cancers has led to the
development of vaccines as preventives, such as vaccines
against human papillomaviruses, the main cause of cervical cancer in women.
«Helping fund the
development of the rapid diagnostic tool is just one way we are investing in and are committed to finding a solution
against this
virus,» said Gloria Basse, Vice President, U.S. Pork Business Unit, Zoetis.
Potential new agents are also being investigated that it is hoped will overcome limitations of the current options, which include a narrow antiviral spectrum, ineffectiveness
against latent
virus infections,
development of drug - resistance and toxic side effects.